Renee Butler is a contributing writer at Pharm-Olam. Before devoting her attention to the pharmaceutical industry, the Exeter MBA grad was a finance writer and stock blogger. When she is not writing, Butler enjoys traveling with her dog, attending the symphony, and running marathons.
May 20th, 2021
HOUSTON, Texas, May 10, 2021 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for infectious diseases, vaccines, rare and orphan diseases along with oncology, is now enrolling volunteers in the United Kingdom into a pivotal Phase III COVID-19 vaccine study. Visit ukcovid19study.com for more information about participation. The Phase III “Cov-Compare” trial (VLA2001-301) will compare Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca’s conditionally approved vaccine, Vaxzevria , in a comparative immunogenicity trial. There will be roughly 4,000 people participating in this study. Pharm-Olam is the full-service provider for this study, utilizing leading technology platforms.